Pharmacology of orismilast, a potent and selective PDE4 inhibitor

Overview of attention for article published in Journal of the European Academy of Dermatology & Venereology, January 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#10 of 5,760)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 88 news outlets

blogs: 1 blog

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 11 Mendeley

Summary News Blogs Dimensions citations

So far, Altmetric has seen 1 blog post.

UNION therapys announces positive topline results from investigator-initiated proof-of-concept study OSIRIS of oral orismilast in patients with hidradenitis suppurativa

Oltnews, 21 Jun 2023

Study Demonstrates Clinically Relevant Improvements in Hidradenitis Suppurativa (HS) Patients Receiving 16 Weeks of Orismilast…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.